MORIN-HEIGHTS, QC, Jan. 10, 2017 /CNW Telbec/ - Capital
Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its
wholly owned subsidiary, Technique d'usinage Sinlab Inc.
("Sinlab"), has entered into a Patent License Agreement with
nSequence Center for Advanced Dentistry and National Dentex
Corporation (each, a "Licensee"). As part of the agreement, Sinlab
granted Licensees a non-exclusive worldwide license to make, use,
sell and offer to sell inventions covered by its patents, including
patents relating to its Technobar and Technoguide technologies,
under terms undisclosed for confidentiality reasons.
Unlicensed entities should obtain an appropriate license from
Sinlab by contacting M. Jean Kingsley at
jeanjkingsley@outlook.com.
The Company previously announced settlement and/or license
agreements that include Biomet 3i, LLC (formerly Implant
Innovations, Inc.); Delcam USA,
Inc. and Delcam Holdings, Inc.; Cagenix, Inc.; Dentsply
International Inc.; Nobel Biocare AB; Nobel Biocare Italiana
S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH;
Nobel Biocare Canada, Inc.; Biocad Médical Inc.; Nobel Biocare
USA, LLC; Nobel Biocare Procera,
LLC; 3Shape A/S, exocad America, Inc., MIS Implants Technologies,
Ltd., SICAT Gmbh & Co. KG and James R. Glidewell Dental
Ceramics, Inc. The Company is currently pursuing its licensing
program with other industry participants. The Company cannot
predict the outcome of its ongoing negotiations or of any legal
proceedings it may decide to institute against those entities that
fail or refuse to contract a license. The decision to take legal
proceedings will be based on available information and the
Company's assessment of all relevant facts and circumstances,
including costs involved with such proceedings. Such costs are
unpredictable and may be substantial.
Caution regarding forward-looking statements
This news release contains certain forward-looking statements
regarding the Company's expectation of future events, including
potential claims and the institution of legal proceedings. Such
expectations are based on certain assumptions based on currently
available information. If these assumptions prove incorrect, actual
results may differ materially from those contemplated by the
forward-looking statements contained in this press release. Factors
that could lead actual results to differ include, amongst others,
factors that may impact claims and legal proceedings, such as
interpretation of factual matters, time and money involved in
undertaking legal proceedings, uncertainty as to the final result
and other risks. The Company disclaims any intention or obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
other than as required by securities laws.
About Pro-Égaux Inc.
Pro-Égaux through its wholly owned subsidiary, Technique
d'usinage Sinlab Inc., is a company based in Lachenaie, Quebec, specializing mainly in the
conception and design of titanium products to be used in the dental
prosthesis restoration industry.
Neither NEX, the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of NEX
and the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
SOURCE Capital Pro-Egaux Inc.